Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The first interchangeable biosimilar, insulin glargine (Semglee), saw increased dispensing after gaining interchangeable status. This suggests interchangeability can improve patient access and lower costs for biosimilar drugs.
Area Of Science
- Health Economics and Outcomes Research
- Pharmaceutical Policy
- Pharmacoeconomics
Background
- The US Food and Drug Administration (FDA) approved the first interchangeable biosimilar, insulin glargine (Semglee), in 2021, allowing pharmacy substitution.
- The impact of this interchangeable designation on prescription dispensing patterns remained largely unknown prior to this study.
Purpose Of The Study
- To evaluate the effect of Semglee's transition to interchangeable designation on its prescription dispensing.
- To assess the role of interchangeability in the utilization of biosimilar medications.
Main Methods
- An economic evaluation analyzed insulin glargine dispensing data from September 2019 to June 2024.
- Data sources included IQVIA's National Prescription Audit and PayerTrak for US pharmacy dispensing.
- Dispensing changes were assessed before and after the November 2021 interchangeable designation, controlling for formulary changes.
Main Results
- A significant increase in aggregate Semglee/insulin glargine-yfgn dispensing (47.41%) was observed post-interchangeable designation (P=.001).
- Dispensing increased across retail, mail, and long-term care channels, indicating broad utilization growth.
- Insulin glargine-yfgn adoption outpaced Semglee in Medicare Part D, Medicaid, and cash channels after launch.
Conclusions
- The first FDA interchangeable designation for insulin glargine was associated with a substantial increase in its dispensing.
- Interchangeability appears to be a key factor in driving biosimilar utilization and market share.
- This designation holds promise for reducing healthcare costs and improving patient access to biosimilar prescription drugs.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...